GIGA Carbon Neutrality Inc. (GCN) Signs Global Strategic Partnership With Carbon Trade eXchange (CTX)
12.5.2023 07:15:00 EEST | Business Wire | Press release
GIGA Carbon Neutrality Inc. (“GCN”) today announced the signing of a Strategic Partnership Agreement with London-based Carbon Trade eXchange (“CTX”) and its Australian technology parent company Global Environmental Markets (“GEM”) to globally expand CTX technology and trading.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005848/en/
CTX has launched a White Label version of its carbon market technology. The partnership agreement will enable GCN to negotiate deals with carbon trading platforms and regular stock exchanges worldwide to provide buyers spot market access to carbon credits, RECs (Renewable Energy Certificates), and offsets. Thus, an AI and blockchain-technology-powered global carbon marketplace will be created featuring carbon futures contracts based on trusted high-quality carbon credits from hundreds of projects in multiple carbon registries. These include the UNFCCC CDM Registry, Verra VCS, and Gold Standard.
GCN undertakes to support the expansion of the licensing of GEM technology infrastructure for National Carbon Meta-Registries for nations to activate their commitments under the Paris Agreement and the creation of ITMOs or voluntary carbon credits like the recently launched Global Carbon Registry (GCR) and credit standard and the recently released Core Carbon Principles by the Integrity Council for voluntary carbon markets.
CTX, GEM, and GCN will work together to expand origination of voluntary credits globally and execute larger-scale trading of the credits, bringing together the GCN business and financial network with the 15 years of experience embedded in CTX and GEM’s “Technology Infrastructure for the Future of our Planet”.
The CEO of CTX, Wayne Sharpe, stated: “The current carbon markets must scale by a factor of 10 to 100X to reduce CO2 emissions globally and meet the Paris Agreement targets. Current registry infrastructure is insufficient.
Stock Exchanges globally are struggling to handle the unique carbon trading requirements in the voluntary markets – which deliver the much-needed Climate Finance via Carbon Credits. CTX will supply and support the required technology – then the buyers decide ”
The CEO of GCN, Richard Martin, added that “this Strategic Partnership Agreement is a big opportunity for GCN to use its extensive network of partners, affiliates, and investors to fast track our global expansion plans with a proven set of carbon technology infrastructure”.
About Carbon Trade eXchange (CTX): CTX is the world's first and leading Voluntary Carbon Exchange trading multiple credit standards and project types with transparent wholesale pricing. Trading out of HQ in London since 2008, CTX services over 500 members in more than 50 countries worldwide with T+0 trades online 24/7/365.
About Global Environmental Markets (GEM): GEM designs and develops environmental FinTech solutions including trading platforms, exchanges, registries, and interfaces. Headquartered in Australia GEM owns the CTX technology IP plus a suite of B2B / B2C solutions.
About GIGA Carbon Neutrality Inc. (GCN): GCN is a service and product integrator in the global intelligent commercial transportation and equipment market to efficiently realize customers’ carbon neutrality goals. GCN and its partners offer vehicle equipment manufacturing, comprehensive technologies, operation platforms, energy data and carbon credit services. For more information, please visit the website: https://gigacarbonneutrality.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005848/en/
Contact information
CTX/GEM:
Wayne Sharpe, info@ctxglobal.com, +447502229523, www.ctxglobal.com, www.gemglobal.com
GCN
Timothy Poor
Email: timothy.poor@gigacarbonneutrality.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom